Literature DB >> 10861460

Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.

S Sutcliffe1, P D Pharoah, D F Easton, B A Ponder.   

Abstract

There are few published estimates of the risk of developing breast or ovarian cancer in women with a strong family history of ovarian cancer. As these women commonly present to family cancer clinics, accurate cancer risk estimates are needed. We have estimated these risks in women from families with 2 or more confirmed ovarian cancers in first-degree relatives using data from the UKCCCR Familial Ovarian Cancer Register. The number of cancers observed in more than 10,000 person years of follow-up was compared with the number expected based on national-, age-, sex- and period-specific incidence rates. The relative risk of ovarian cancer was found to be 7.18 (95% CI 3.82-12.3), declining from 16.0 (6.40-32.9) in women under 50 to 4.38 (1.60-9.52) in women 50 years of age and older. For breast cancer, the relative risk for women under 50 was 3.74 (2.04-6. 28) and 1.79 (1.02-2.90) for women 50 years of age and older (average RR 2.36, 1.59-3.37). These correspond to absolute risks by age 70 of 11% for ovarian cancer and 15% for breast cancer. When the analyses were restricted to families that had been negative for mutations in the breast/ovarian cancer susceptibility genes, BRCA1 and BRCA2, the ovarian cancer risk was 11.59 (3.12-29.7) and that of breast cancer 3.32 (1.52-6.31). As well as having clinical relevance, our finding may suggest that other breast/ovarian cancer genes are segregating in these families, though the possibility of undetected BRCA1/2 mutations must also be considered. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861460     DOI: 10.1002/1097-0215(20000701)87:1<110::aid-ijc16>3.0.co;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Risk assessment and management of high risk familial breast cancer.

Authors:  D G R Evans; F Lalloo
Journal:  J Med Genet       Date:  2002-12       Impact factor: 6.318

2.  Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy.

Authors:  Lennart J van Winden; Ravi F M Vermeulen; Vincent van den Noort; Katja N Gaarenstroom; Gemma G Kenter; Monique M A Brood-van Zanten; Catharina M Korse; Marc van Beurden; Huub H van Rossum
Journal:  J Endocr Soc       Date:  2022-04-25

3.  Premature or early bilateral oophorectomy: a 2021 update.

Authors:  W A Rocca; M M Mielke; L Gazzuola Rocca; E A Stewart
Journal:  Climacteric       Date:  2021-03-15       Impact factor: 3.024

4.  Epidemiology of ovarian cancer: a review.

Authors:  Brett M Reid; Jennifer B Permuth; Thomas A Sellers
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

5.  Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.

Authors:  Rita Kukafka; Samuel Pan; Thomas Silverman; Tianmai Zhang; Wendy K Chung; Mary Beth Terry; Elaine Fleck; Richard G Younge; Meghna S Trivedi; Julia E McGuinness; Ting He; Jill Dimond; Katherine D Crew
Journal:  JAMA Netw Open       Date:  2022-07-01

6.  Surveillance of women at high risk for hereditary ovarian cancer is inefficient.

Authors:  A L Oei; L F Massuger; J Bulten; M J Ligtenberg; N Hoogerbrugge; J A de Hullu
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.